MARKET

BCDAW

Biocardia
BCDAW
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-1.0355
0.0202
-0.0048
-
BioCardia präsentiert neue Echokardiographie-Daten aus der CardiAMP-HF-Studie
Reuters · 02/03 13:02
BioCardia Unveils Late-Breaking CardiAMP HF Trial Echocardiography Results at THT Meeting
Reuters · 02/03 13:02
BIOCARDIA ANNOUNCES LATE BREAKING ECHOCARDIOGRAPHY RESULTS FROM THE CARDIAMP HF TRIAL TO BE PRESENTED AT TECHNOLOGY AND HEART FAILURE THERAPEUTICS (THT)
Reuters · 02/03 13:00
BioCardia CEO Peter Altman Reports Disposal of Common Shares
Reuters · 01/21 22:03
BioCardia CEO Peter Altman Reports Disposal of Common Shares
Reuters · 12/17/2025 23:33
BIOCARDIA CELL THERAPY FOR ISCHEMIC HEART FAILURE TO PROGRESS TO FORMAL CLINICAL CONSULTATION WITH JAPAN PMDA
Reuters · 12/16/2025 13:01
BioCardia Inc. Files Initial Beneficial Ownership Statement for Director Marvin Slosman
Reuters · 12/11/2025 02:48
BioCardia Appoints Marvin Slosman to Board as Richard Krasno Departs
Reuters · 12/03/2025 13:01
More

Webull offers Biocardia stock information, including NASDAQ: BCDAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCDAW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCDAW stock methods without spending real money on the virtual paper trading platform.